Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside

Kidney Research and Clinical Practice

Volumn 31, Issue 3, 2012, Pages 132-138

  Kim, Hyun Jung ^a,b   Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Everolimus; Mammalian target of rapamycin; Polycystic kidney; Polycystic kidney disease; Sirolimus

Indexed keywords

CURCUMIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PLACEBO; POLYCYSTIN 1; POLYCYSTIN 2; RAPAMYCIN;

ACNE; ANEMIA; ANGIONEUROTIC EDEMA; APHTHOUS ULCER; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIARRHEA; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL DISEASE; GENE; GENE MUTATION; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; KIDNEY TUBULE CELL; LEUKOPENIA; LOW DRUG DOSE; MUCOSA INFLAMMATION; NONHUMAN; ORTHOLOGY; PATHOGENESIS; PKD1 GENE; PKD2 GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84879194299     PISSN: 22119132     EISSN: 22119140     Source Type: Journal    
DOI: 10.1016/j.krcp.2012.07.002     Document Type: Review

References (47)

1. P.A. Gabow Autosomal dominant polycystic kidney disease N Engl J Med 329 1993 332 342
2. S.M. Nauli, F.J. Alenghat, Y. Luo, E. Williams, P. Vassilev, X. Li, A.E. Elia, W. Lu, E.M. Brown, S.J. Quinn, D.E. Ingber, and J. Zhou Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells Nat Genet 33 2003 129 137
3. F. Belibi, and C.L. Edelstein Novel targets for the treatment of autosomal dominant polycystic kidney disease Expert Opin Investig Drugs 19 2010 315 328
4. M. Chang, and A.C. Ong Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects Nephron Clin Pract 120 2012 c25 c35
5. P.D. Wilson Polycystic kidney disease N Engl J Med 350 2004 151 164
6. M. Trudel, V. D'Agati, and F. Costantini C-myc as an inducer of polycystic kidney disease in transgenic mice Kidney Int 39 1991 665 671
7. D.L. Schaffner, R. Barrios, C. Massey, E.I. Bañez, C.N. Ou, S. Rajagopalan, E. Aguilar-Cordova, R.M. Lebovitz, P.A. Overbeek, and M.W. Lieberman Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys Am J Pathol 142 1993 1051 1060
8. D.C. Fingar, and J. Blenis Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene 23 2004 3151 3171
9. V.E. Torres, A. Boletta, A. Chapman, V. Gattone, Y. Pei, Q. Qian, D.P. Wallace, T. Weimbs, and R.P. Wüthrich Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases Clin J Am Soc Nephrol 5 2010 1312 1329
10. X. Gao, Y. Zhang, P. Arrazola, O. Hino, T. Kobayashi, R.S. Yeung, B. Ru, and D. Pan Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling Nat Cell Biol 4 2002 699 704
11. K. Hara, Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 2002 177 189
12. P.E. Burnett, R.K. Barrow, N.A. Cohen, S.H. Snyder, and D.M. Sabatini RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 Proc Natl Acad Sci USA 95 1998 1432 1437
13. N. Oshiro, K. Yoshino, S. Hidayat, C. Tokunaga, K. Hara, S. Eguchi, J. Avruch, and K. Yonezawa Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function Genes Cells 9 2004 359 366
14. J. Huang, and B.D. Manning A complex interplay between Akt, TSC2 and the two mTOR complexes Biochem Soc Trans 37 2009 217 222
15. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
16. K.G. Foster, and D.C. Fingar Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony J Biol Chem 285 2010 14071 14077
17. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
18. C.A. Sparks, and D.A. Guertin Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy Oncogene 29 2010 3733 3744
19. B. Hoang, P. Frost, Y. Shi, E. Belanger, A. Benavides, G. Pezeshkpour, S. Cappia, T. Guglielmelli, J. Gera, and A. Lichtenstein Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor Blood 116 2010 4560 4568
20. G. Martiny-Baron, and D. Fabbro Classical PKC isoforms in cancer Pharmacol Res 55 2007 477 486
21. C. Boehlke, F. Kotsis, V. Patel, S. Braeg, H. Voelker, S. Bredt, T. Beyer, H. Janusch, C. Hamann, M. Gödel, K. Müller, M. Herbst, M. Hornung, M. Doerken, M. Köttgen, R. Nitschke, P. Igarashi, G. Walz, and E.W. Kuehn Primary cilia regulate mTORC1 activity and cell size through Lkb1 Nat Cell Biol 12 2010 1115 1122
22. P.D. Bell, W. Fitzgibbon, K. Sas, A.E. Stenbit, M. Amria, A. Houston, R. Reichert, S. Gilley, G.P. Siegal, J. Bissler, M. Bilgen, P.C. Chou, L. Guay-Woodford, B. Yoder, C.J. Haycraft, and B. Siroky Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis J Am Soc Nephrol 22 2011 839 848
23. J.U. Becker, A.O. Saez, K. Zerres, O. Witzke, P.F. Hoyer, K.W. Schmid, A. Kribben, C. Bergmann, and J. Nurnberger The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease Kidney Blood Press Res 33 2010 129 138
24. D.C. Fischer, U. Jacoby, L. Pape, C.J. Ward, E. Kuwertz-Broeking, C. Renken, H. Nizze, U. Querfeld, B. Rudolph, D.E. Mueller-Wiefel, C. Bergmann, and D. Haffner Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD) Nephrol Dial Transplant 24 2009 1819 1827
25. Y. Tao, J. Kim, R.W. Schrier, and C.L. Edelstein Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD) J Am Soc Nephrol 16 2005 46 51
26. P.R. Wahl, A.L. Serra, M. Le Hir, K.D. Molle, M.N. Hall, and R.P. Wüthrich Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD) Nephrol Dial Transplant 21 2006 598 604
27. M. Wu, P.R. Wahl, M. Le Hir, Y. Wackerle-Men, R.P. Wuthrich, and A.L. Serra Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease Kidney Blood Press Res 30 2007 253 259
28. J.M. Shillingford, N.S. Murcia, C.H. Larson, S.H. Low, R. Hedgepeth, N. Brown, C.A. Flask, A.C. Novick, D.A. Goldfarb, A. Kramer-Zucker, G. Walz, K.B. Piontek, G.G. Germino, and T. Weimbs The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease Proc Natl Acad Sci USA 103 2006 5466 5471
29. I. Zafar, F.A. Belibi, Z. He, and C.L. Edelstein Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD) Nephrol Dial Transplant 24 2009 2349 2353
30. F. Belibi, K. Ravichandran, I. Zafar, Z. He, and C.L. Edelstein mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease Am J Physiol Renal Physiol 300 2011 F236 F244
31. J.M. Shillingford, K.B. Piontek, G.G. Germino, and T. Weimbs Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1 J Am Soc Nephrol 21 2010 489 497
32. I. Zafar, K. Ravichandran, F. Belibi, R.B. Doctor, and C.L. Edelstein Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease Kidney Int 78 2010 754 761
33. M. Wu, A. Arcaro, Z. Varga, A. Vogetseder, M. Le Hir, R.P. Wuthrich, and A.L. Serra Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease Am J Physiol Renal Physiol 297 2012 F1597 F1605
34. C. Renken, D.C. Fischer, G. Kundt, N. Gretz, and D. Haffner Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats Nephrol Dial Transplant 26 2011 92 100
35. Z. Novalic, A.M. van der Wal, W.N. Leonhard, G. Keohl, M.H. Breuning, E.K. Geissler, E. de Heer, and D.J. Peters Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease J Am Soc Nephrol 23 2012 842 853
36. V. Takiar, S. Nishio, P. Seo-Mayer, J.D. King Jr., H. Li, L. Zhang, A. Karihaloo, K.R. Hallows, S. Somlo, and M.J. Caplan Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis Proc Natl Acad Sci USA 106 2011 2462 2467
37. S. Anderson, T.T. Oyama, J.N. Lindsley, W.E. Schutzer, D.R. Beard, V.H. Gattone, and R. Komers 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease Am J Physiol Renal Physiol 302 2012 F636 F645
38. S. Qin, M. Taglienti, S.M. Nauli, L. Contrino, A. Takakura, J. Zhou, and J.A. Kreidberg Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease J Clin Invest 120 2010 3617 3628
39. Q. Qian, D. Hui, B.F. King, S. Kumar, P.G. Dean, F.G. Cosio, and V.E. Torres Sirolimus reduces polycystic liver volume in ADPKD patients J Am Soc Nephrol 19 2008 631 638
40. N. Perico, L. Antiga, A. Caroli, P. Ruggenenti, G. Fasolini, M. Cafaro, P. Ondei, N. Rubis, O. Diadei, G. Gherardi, S. Prandini, A. Panozo, R.F. Bravo, S. Carminati, F.R. De Leon, F. Gaspari, M. Cortinovis, N. Motterlini, B. Ene-Iordache, A. Remuzzi, and G. Remuzzi Sirolimus therapy to halt the progression of ADPKD J Am Soc Nephrol 21 2010 1031 1040
41. G. Walz, K. Budde, M. Mannaa, J. Nurnberger, C. Wanner, C. Sommerer, U. Kunzendorf, B. Banas, W.H. Hörl, N. Obermüller, W. Arns, H. Pavenstädt, J. Gaedeke, M. Büchert, C. May, H. Gschaidmeier, S. Kramer, and K.U. Eckardt Everolimus in patients with autosomal dominant polycystic kidney disease New Engl J Med 363 2010 830 840
42. A.L. Serra, D. Poster, A.D. Kistler, F. Krauer, S. Raina, J. Young, K.M. Rentsch, K.S. Spanaus, O. Senn, P. Kristanto, H. Scheffel, D. Weishaupt, and R.P. Wüthrich Sirolimus and kidney growth in autosomal dominant polycystic kidney disease New Engl J Med 363 2010 820 829
43. T. Watnick, and G.G. Germino mTOR inhibitors in polycystic kidney disease New Engl J Med 363 2010 879 881
44. N. Perico, and G. Remuzzi Do mTOR inhibitors still have a future in ADPKD? Nar Rev Nephrol 6 2010 696 698
45. G. Canaud, B. Knebelmann, P.C. Harris, F. Vrtovsnik, and J.M. Correas Pallet N, Heyer CM, Letavernier E, Bienaimé F, Thervet E, Martinez F, Terzi F, Legendre C: Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant 10 2010 1701 1706
46. C. Ponticelli, and F. Locatelli Autosomal dominant polycystic kidney disease and mTOR inhibitors:the narrow road between hope and disappointment Nephrol Dial Transplant 25 2010 3809 3812
47. B. Shor, J.J. Gibbons, R.T. Abraham, and K. Yu Targeting mTOR globally in cancer; thinking beyond rapamycin Cell Cycle 8 2009 3831 3837